Jun 04, 2021 / 08:00PM GMT
Operator
I'm the operator today for Amgen's conference call from ASCO. (Operator Instructions) I would now like to introduce Arvind Sood, Vice President of Investor Relations. Mr. Sood, you may now begin.
Arvind Sood - Amgen Inc. - VP of IR
Thank you, Erica. Good afternoon, everyone. Welcome, and we very much appreciate your participation in our ASCO event. We have presented important data at this conference and very much looking forward to the discussion. Presenting from Amgen will be our Executive Vice President of Research and Development, Dr. David Reese, who will briefly review our oncology portfolio strategy, followed by our Vice President of Global Development, Dr. Greg Friberg. Greg will review the Lumakras data in non-small cell lung cancer followed by Dr. P.K. Morrow, who is also a Vice President of Global Development. P.K. will then review the bemarituzumab data in gastric cancer and Tarlatamab data in small cell lung cancer.
Tarlatamab, by the way, is our DLL3 targeting BiTE also known as AMG 757. Don't worry about taking pictures of the slides as a
Amgen Inc Conference Call from ASCO Transcript
Jun 05, 2021
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers